| Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells. | |
| | |
MedLine Citation:
|
PMID: 18225541 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Bisphosphonates are considered to be effective in preventing tumor metastasis to bone. Urokinase-type plasminogen activator (uPA) is thought to be critically involved in the metastatic phenotype of prostate cancer. In this study, we examined the effect of pamidronate on uPA expression in PC-3 prostate cancer cells. MATERIALS AND: The mRNA expression of uPA was assayed by real-time RT-PCR. The transcriptional activity of uPA was measured by a luciferase assay. RESULTS: Pamidronate inhibited uPA mRNA expression by about 90% at 24 h. The inhibition of uPA mRNA expression was prevented in part by cotreatment with geranylgeranyl diphosphate (GGPP). Moreover, GGTI-286, a selective inhibitor of geranylgeranyl transferase, also inhibited uPA mRNA expression. The luciferase activity of uPA reporter plasmid was significantly inhibited by pamidronate. CONCLUSION: These results indicate that the decrease in uPA expression brought about by pamidronate is dependent on the inhibition of geranylgeranylation of proteins and occurs at the transcriptional level. |
| | |
Authors:
|
Kazuhiro Iguchi; Yoshiki Tatsuda; Shigeyuki Usui; Kazuyuki Hirano |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Anticancer research Volume: 27 ISSN: 0250-7005 ISO Abbreviation: Anticancer Res. Publication Date: 2007 Nov-Dec |
Date Detail:
|
Created Date: 2008-01-29 Completed Date: 2008-02-12 Revised Date: 2010-10-19 |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 3843-8 Citation Subset: IM |
Affiliation:
|
Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
pharmacology* Cell Line, Tumor Diphosphonates / pharmacology* Diterpenes / pharmacology Down-Regulation / drug effects Humans Male Polyisoprenyl Phosphates / pharmacology Prostatic Neoplasms / drug therapy*, enzymology*, genetics RNA, Messenger / biosynthesis, genetics Serine Proteinase Inhibitors / pharmacology Transcription, Genetic / drug effects Urokinase-Type Plasminogen Activator / antagonists & inhibitors*, biosynthesis, genetics |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Diphosphonates; 0/Diterpenes; 0/Polyisoprenyl Phosphates; 0/RNA, Messenger; 0/Serine Proteinase Inhibitors; 40391-99-9/pamidronate; 6699-20-3/geranylgeranyl pyrophosphate; EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leu...
Next Document: Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cance...